Kauliv (Teriparatide)

Teriparatide mimics the action of natural parathyroid hormone by binding to the PTH1 receptor on bone‑forming cells called osteoblasts. This activates signaling pathways that stimulate osteoblast proliferation, collagen production, and mineralization, leading to net bone gain when the drug is given intermittently.

The specific dose and treatment schedule for Kauliv are determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response to therapy. Physicians follow approved labeling and clinical guidelines to set the appropriate regimen.

Safety of teriparatide in pregnancy or while nursing has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified prescriber.

To place an order, submit an enquiry on the Kauliv product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

Kauliv is a bone‑forming (anabolic) therapy, whereas many other osteoporosis drugs, such as bisphosphonates or denosumab, are anti‑resorptive agents that slow bone loss. Teriparatide directly stimulates new bone formation, offering a different mechanism that can be advantageous for patients with severe bone loss or who have not responded to anti‑resorptive therapy.

Kauliv should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. Maintaining the cold chain preserves the stability and efficacy of the teriparatide formulation.

Kauliv is given as a subcutaneous injection, typically into the thigh or abdomen. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient themselves using a pre‑filled pen or syringe, following the dosing schedule prescribed by the clinician.

The most serious risks include the rare possibility of osteosarcoma, severe hypercalcemia, and serious allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of elevated calcium levels, unexplained bone pain, or any hypersensitivity symptoms, and therapy should be discontinued if these occur.

Kauliv is contraindicated in individuals with existing hypercalcemia, active bone malignancies (including osteosarcoma), a history of skeletal radiation therapy, or those who are pregnant or breastfeeding unless the prescriber determines the benefits outweigh the risks. Patients with severe renal impairment should also be evaluated carefully before use.